Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
| dc.contributor.author | Muthanna K. Zaki1, Mohammed N. Abed2, Fawaz A. Alassaf1 | |
| dc.date.accessioned | 2026-09-21T08:32:23Z | |
| dc.date.issued | 2024 | |
| dc.identifier.citation | 10.11005/jbm.2024.31.3.169 | |
| dc.identifier.issn | 2287-6375 | |
| dc.identifier.uri | https://drcentrallibrary.uomosul.edu.iq/handle/123456789/8698 | |
| dc.language.iso | en | |
| dc.publisher | جامعة الموصل /University of Mosul | |
| dc.relation.ispartofseries | 255R | |
| dc.subject | Antidiabetic agents. | |
| dc.subject | Bone · | |
| dc.subject | Diabetes Mellitus · | |
| dc.subject | Glycation | |
| dc.subject | Incretin | |
| dc.title | Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations | |
| dc.type | Other |